| 1. |
- Bergfeldt, Kjell, et al.
(författare)
-
”Livet efter cancer är inte en angelägenhet bara för vården”
- 2024
-
Ingår i: Dagens medicin. - 1104-7488 .- 1402-1943. ; :2024-03-12
-
Tidskriftsartikel (populärvet., debatt m.m.)abstract
- Fem debattörer från Cancerrehabfondens vetenskapliga råd ställer sig frågan: förstår riksdag och regering fullt ut betydelsen av civilsamhällets roll för den svenska välfärden?
|
|
| 2. |
- Bergfeldt, Kjell
(författare)
-
Malignancies associated with gynecological cancer : epidemiological and etiological aspects
- 2001
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- The aims of this thesis were to analyze the incidence and risk of second primary malignancies (SPM) in a Swedish cohort of gynecological cancer patients, to explore suggested risk factors associated with second primary malignancies in ovarian cancer patients, and to evaluate the risk of ovarian cancer in a cohort of breast cancer patients in relation to family history of breast or ovarian cancer. Incidence of second primary malignancies in 15,200 gynecologicaI cancer patients were investigated in a register-based study and compared to age- and calendar-specific incidence for women in the general population. Increased risk of leukemia was found after ovarian and endometrial cancer. Additional sites of excess risk in ovarian cancer patients were breast, endometrial, colon, rectum, and bladder, while women with endometrial cancer were documented having an increased risk of cancer of the colon, ovaries, vulva, and bladder. Cervical cancer patients were found with increased risk of cancer of colon, rectum, lung, vulva, kidney, and bladder (Paper I). Validity of register data was investigated by comparisons with hospital records for 347 women registered with ovarian cancer and one or more second primary malignancy. Errors in cancer registrations were revealed concerning the first as well as the second primary cancer, although previously risk estimates remained increased when corrected for registration errors (H). In a multi-center case-control study, platinum-based chemotherapy was shown to be highly associated with an increased risk of leukemia (HI). The risk of second primary breast cancer in women with ovarian cancer was associated with heredity, nulliparity, and late menopause. Furthermore, 43 % of the breast cancer cases were diagnosed without symptoms of the disease in line of routine follow-up, indicating clinical surveillance to be important when reflecting the incidence of SPM (IV). In order to further investigate family history as a risk factor, the risk of ovarian cancer in breast cancer patients was analyzed using data from the Swedish Generation Register. Breast cancer patients with a family history of breast or notably ovarian cancer were found to be at high risk of subsequent ovarian cancer (V). The results confirm that women with gynecological cancer have an increased risk of second primary malignancies at certain sites, knowledge that should be considered in clinical follow-up. In ovarian cancer patients, a part of the excess risk of subsequent malignancies could be referred to register errors and intense clinical surveillance. Regarding the appearance of ovarian cancer as a second primary malignancy in breast cancer patients, the risk was found to be high in young women with a family history of breast or ovarian cancer, implementing the need of intense clinical surveillance in high-risk groups, even considering prophylactic oophorectomy in selected cases.
|
|
| 3. |
|
|
| 4. |
- Högberg, Thomas, et al.
(författare)
-
Hopp om förbättring av överlevnad i ovarialcancer
- 2015
-
Ingår i: Läkartidningen. - : Läkartidningen Förlag AB. - 0023-7205 .- 1652-7518. ; 112:50, s. 2281-3
-
Tidskriftsartikel (refereegranskat)abstract
- Ovarian cancer is the most common cause of death from a gynecologic cancer. Every year around 700 women contracts ovarian cancer in Sweden. The overall survival is among the highest in Europe, but still long term relative survival is only 46%. It is a long-held myth that ovarian cancer is a disease without symptoms. Almost 90% of women have symptoms, even in the early stages. Symptoms that should arise suspicion of ovarian cancer and initiate diagnostic work-up are continuous abdominal extension, early feeling of satiety, pelvic or abdominal pain, urinary urge and postmenopausal bleeding. Women's awareness of symptoms and willingness to seek medical advice and the organization of the health care system are important factors determining cancer survival. Ovarian cancer is a heterogeneous group of diseases with different tumor traits and prognosis. Personalized medicine and preventive measures recognizing recent knowledge about tumor biology will positively affect survival.
|
|
| 5. |
- Högberg, Thomas, et al.
(författare)
-
Hopp om förbättring av överlevnad i ovarialcancer
- 2015
-
Ingår i: Läkartidningen. - : Läkartidningen Förlag AB. - 1652-7518 .- 0023-7205. ; 112
-
Tidskriftsartikel (refereegranskat)abstract
- Ovarian cancer is the most common cause of death from a gynecologic cancer. Every year around 700 women contracts ovarian cancer in Sweden. The overall survival is among the highest in Europe, but still long term relative survival is only 46%. It is a long-held myth that ovarian cancer is a disease without symptoms. Almost 90% of women have symptoms, even in the early stages. Symptoms that should arise suspicion of ovarian cancer and initiate diagnostic work-up are continuous abdominal extension, early feeling of satiety, pelvic or abdominal pain, urinary urge and postmenopausal bleeding. Women's awareness of symptoms and willingness to seek medical advice and the organization of the health care system are important factors determining cancer survival. Ovarian cancer is a heterogeneous group of diseases with different tumor traits and prognosis. Personalized medicine and preventive measures recognizing recent knowledge about tumor biology will positively affect survival.
|
|
| 6. |
- Kalapotharakos, Grigorios, et al.
(författare)
-
Long term survival in women with borderline ovarian tumors: a population-based survey of borderline ovarian tumors in Sweden 1960-2007.
- 2016
-
Ingår i: Acta Obstetricia et Gynecologica Scandinavica. - : Wiley. - 1600-0412 .- 0001-6349. ; 95:4, s. 473-479
-
Tidskriftsartikel (refereegranskat)abstract
- Evaluation of incidence and survival of patients with borderline ovarian tumors in Sweden MATERIAL AND METHODS: All women diagnosed with borderline ovarian tumor in the Swedish Cancer Register 1960-2007 (n=6,252) combined with follow-up in the Swedish Death Registry to 1 July 2009 were included. Estimation of age-standardized relative survival rate according to time periods for diagnosis RESULTS: The incidence of borderline ovarian tumors increased during the study period, with a steep increase during the 1980-ies. The age standardized 5 year relative survival including all borderline tumors diagnosed 2000-2007 was 97% (95% confidence interval: 92-99%). In women age 64 or younger 10 year relative survival related to age at diagnosis of borderline tumors ranged from 95 to 98% and were 89% in women 65-74. In a multivariable analysis including age and decade of diagnosis relative survival for every decade increased. The 10-year relative survival in patients with mucinous and serous borderline tumors did not differ significantly (p=0.121).
|
|
| 7. |
- Olsson, Caroline, 1970, et al.
(författare)
-
Initial experience with introducing national guidelines for CT- and MRI-based delineation of organs at risk in radiotherapy
- 2019
-
Ingår i: Physics and Imaging in Radiation Oncology. - : Elsevier. - 2405-6316. ; 11, s. 88-91
-
Tidskriftsartikel (refereegranskat)abstract
- A fundamental problem in radiotherapy is the variation of organ at risk (OAR) volumes. Here we present our initial experience in engaging a large Radiation Oncology (RO) community to agree on national guidelines for OAR delineations. Our project builds on associated standardization initiatives and invites professionals from all radiotherapy departments nationwide. Presently, one guideline (rectum) has successfully been agreed on by a majority vote. Reaching out to all relevant parties in a timely manner and motivating funding agencies to support the work represented early challenges. Population-based data and a scalable methodological approach are major strengths of the proposed strategy.
|
|
| 8. |
- Sanner, Karin, 1961-, et al.
(författare)
-
Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden
- 2009
-
Ingår i: Fertil Steril. - : Elsevier BV. ; 91:4, s. 1152-1158
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE: To study the association between hormonal infertility treatment and ovarian neoplasia. DESIGN: Historical cohort study. SETTING: Three university hospitals in Sweden. PATIENT(S): A total of 2,768 women assessed and treated for infertility and infertility-associated disorders between 1961 and 1975. INTERVENTION(S): Exposed women received clomiphene citrate and/or gonadotropins. MAIN OUTCOME MEASURE(S): Incidence of ovarian neoplasia. RESULT(S): No overall excess risk of invasive ovarian cancer emerged compared with the general population. In women with gonadotropin treatment for non-ovulatory disorders, the risk was elevated (standardized incidence ratio [SIR] = 5.89; 95% confidence interval [CI] 1.91-13.75); four of the five cases reported hCG treatment only, rendering the biological plausibility uncertain. Multivariate analysis within the cohort indicated that treatment with gonadotropins only was associated with an increased risk of invasive cancer (relative risk = 5.28; 95% CI 1.70-16.47). For borderline tumors, a more than threefold overall increase of tumors (SIR = 3.61; 95% CI 1.45-7.44) was noted; women exposed to clomiphene because of ovulatory disorders showed the highest risk (SIR = 7.47; 95% CI 1.54-21.83). CONCLUSION(S): Our findings of increased risk of ovarian cancer after gonadotropins and of borderline tumors after clomiphene treatment need to be interpreted with caution. However, concern is raised, and further research on the long-term safety particularly of modern hormonal infertility treatment in IVF programs is warranted.
|
|
| 9. |
- Steffensen, Karina Dahl, et al.
(författare)
-
Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study.
- 2013
-
Ingår i: International Journal of Gynecological Cancer. - 1048-891X. ; 23:1, s. 73-80
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE: The increasing number of negative trials for ovarian cancer treatment has prompted an evaluation of new biologic agents, which in combination with chemotherapy may improve survival. The aim of this study was to investigate the response rate in platinum-resistant, KRAS wild-type ovarian cancer patients treated with pegylated liposomal doxorubicin (PLD) supplemented with panitumumab. PATIENTS AND METHODS: Major eligibility criteria were relapsed ovarian/fallopian/peritoneal cancer patients with platinum-resistant disease, measurable disease by GCIG CA125 criteria and KRAS wild-type. Patients were treated with panitumumab 6 mg/kg day 1 and day 15 and with PLD 40 mg/m day 1, every 4 weeks. RESULTS: Forty-six patients were enrolled by 6 study sites in this multi-institutional phase II trial. The response rate in the intention-to-treat population (n = 43) was 18.6%. Progression-free and overall survival in the intention-to-treat population was 2.7 months (2.5-3.2 months, 95% confidence interval) and 8.1 months (5.6-11.7 months, 95% confidence interval), respectively. The most common treatment-related grade 3 toxicities included skin toxicity (42%), fatigue (19%), and vomiting (12%). CONCLUSIONS: The combination of PLD and panitumumab demonstrates efficacy in platinum refractory/resistant patients but the skin toxicity was considerable.
|
|
| 10. |
|
|
